Top 5 Drug Type | Count |
---|---|
Synthetic peptide vaccine | 3 |
Biological products | 3 |
Diagnostic radiopharmaceuticals | 2 |
Personalized antigen vaccine | 2 |
Therapeutic vaccine | 2 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CNGA3 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date11 Oct 2023 |
Sponsor / Collaborator |
Start Date01 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AAV8-CNGA3 gene therapy(Universitaetsklinikum Tuebingen) ( CNGA3 ) | Color Vision Defects More | Phase 2 |
Multipeptide vaccine(German Consortium For Translational Cancer Research) | Renal Cell Carcinoma More | Phase 2 |
IMA-970A | Hepatocellular Carcinoma More | Phase 2 |
Multipeptide-based immunotherapy(German Consortium For Translational Cancer Research) | Prostatic Cancer More | Phase 2 |
Recombinant Hybrid GMZ-2(Statens Serum Institute) | Malaria, Vivax More | Phase 2 |